Drug Profile
Salmeterol inhalation aerosol - GlaxoSmithKline
Alternative Names: Salmeter; Serevent Inhalation Aerosol; Serevent Inhaler; Serevent MDI; SerobidLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Allen & Hanburys; GlaxoSmithKline
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Market Withdrawal Asthma; Bronchitis; Chronic obstructive pulmonary disease
Most Recent Events
- 19 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 03 Oct 2000 Launched for Bronchitis in New Zealand (Inhalation)
- 31 Dec 1999 Launched for Asthma in India (Inhalation)